ESCRS - PO1063 - Oral Propranolol Therapy For A Pediatric Choroidal Hemangioma

Oral Propranolol Therapy For A Pediatric Choroidal Hemangioma

Published 2023 - 41st Congress of the ESCRS

Reference: PO1063 | Type: Free paper | DOI: 10.82333/mf0r-df05

Authors: Mahmoud Mustafa Mahmoud Mustafa* 1 , Ghada Elnady 1

1Pediatric ophthalmology ,Alexandria General Ophthalmology Hospital,Alexandria,Egypt

Purpose

To evaluate the effectiveness of oral propranolol in the treatment of exudative retinal detachment secondary to choroidal heamangiomas.

Setting

A case Report

Methods

We administered oral propranolol at a dose of 1.5mg/kg/day to 8 years girl with circumscribed choroidal heamangioma and exudative retinal detachment 
We then evaluated the visual acuity, indirect ophthalmoscope, fundus photo,ultrasound at regular intervals and compared changes from the base line assessment.

Results

The study showed that the RD slowly resolved over 3 months with improvement of the visual acuity and the retina remained attached at 3 months follow up.

Conclusions

Oral propranolol can prove to be an effective non invasive therapy in children having choroidal hemangioma with exudative retinal detachment.